[1] Global reporton the epidemiology and burdenof sepsis: currentevidence, identifying gapsand future directions. Geneva: WHO; 2020.Licence: CC BYNCSA3.0 IGO.
[2] https://solidaritessante.gouv.fr/
[3] Angus DC, et al. Epidemiology of severe sepsisin the United States: Analysisof incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:13031310.
[4] Levy MM, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohortstudy. Lancet Inf Dis. 2012; 12:919924.
[5] Nestrigue C, Or Z. Estimation du surcoût des événements indésirables associés aux soins à l’hôpital en France. Rapportde l’IRDES 2012/02.
[6] C. Adrie, et al. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site,and place of acquisition (community, hospital, or intensivecare unit) as determinants of workload and cost. J.Critical Care, 2005 Mar;20(1):4658.
[7] Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3). JAMA. 2016;315:80110.
[8] Annane D. Sepsis – Tous unis contre un fléau méconnu. Rapport au DGS. Septembre 2018. https://solidaritessante.gouv.fr/IMG/pdf/rapport_sepsis_dgs_130919.pdf.
[9] Kumar A, et al. Duration of hypotension beforeinitiation of effectiveantimicrobial therapy is the criticaldeterminant of survivalin human septicshock. Crit Care Med. 2006;34:158996.
[10] CASFM/EUCAST : SFM Ed. Recommandations 2021 V.1.0, avril.
[11] Babowicz F, et al. Impact of Accelerate Pheno and BacT/Alert Virtuo on clinical processes and outcomes in patients with sepsis and concurrent gramnegative bacteremia. Antimicrob Agents Chemother. 2021;65:e0236420.